Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 271 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: EYLEA Clear all

Conditions: Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
Interventions: Tiespectus, Aflibercept; Drug
Lead sponsor: EyeBiotech Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 52
States / cities: Gilbert, Arizona • Encino, California • Mountain View, California + 49 more

Conditions: Neovascular Age Related Macular Degeneration
Interventions: VEGF Trap, VEGF Trap; Drug · Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 6
States / cities: Fort Myers, Florida • Wichita, Kansas • Hagerstown, Maryland + 3 more

Conditions: Age-Related Macular Degeneration
Interventions: Sirolimus, Standard of Care intravitreal injections of anti-VEGF; Drug
Lead sponsor: Maturi, Raj K., M.D., P.C.; Individual
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Diabetic Retinopathy
Interventions: BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 40
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more

Conditions: Cystoid Macular Edema, Diabetic Macular Edema
Interventions: Intravitreal Aflibercept Injection; Drug
Lead sponsor: California Retina Consultants; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Bakersfield, California • Santa Barbara, California

Conditions: Diabetic Macular Edema
Interventions: Intravitreal Aflibercept; Drug
Lead sponsor: Southeast Clinical Research Associates, LLC; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Charlotte, North Carolina • Statesville, North Carolina

Conditions: Irvine-Gass Syndrome
Interventions: Aflibercept; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Age-Related Macular Degeneration
Interventions: Ranibizumab, Aflibercept; Drug
Lead sponsor: Associated Retinal Consultants, Michigan; Other
Eligibility: 40 Years and older
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Neovascular Polypoidal Choroidal Vasculopathy
Interventions: Rescue Intravitreal Aflibercept Injection, Rescue Therapy with PDT, Laser or Intravitreal Steroids; Drug · Procedure
Lead sponsor: Southeast Retina Center, Georgia; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Interventions: 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL); Biological
Lead sponsor: 4D Molecular Therapeutics; Industry
Eligibility: 50 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 60
States / cities: Scottsdale, Arizona • Sun City, Arizona • Tucson, Arizona + 55 more

Conditions: Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions: SCD411, Aflibercept; Drug
Lead sponsor: Sam Chun Dang Pharm. Co. Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 12
States / cities: Campbell, California • Clearwater, Florida • Coral Springs, Florida + 9 more

Conditions: Age-related Macular Degeneration
Interventions: Brolucizumab 6 mg, Aflibercept 2 mg; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 734 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 24
States / cities: Phoenix, Arizona • Huntington Beach, California • Loma Linda, California + 20 more

Conditions: Exudative Age Related Macular Degeneration
Interventions: Sirolimus, EYLEA; Drug
Lead sponsor: Maturi, Raj K., M.D., P.C.; Individual
Eligibility: 50 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Neoplasms, Cancer of the Ovary
Interventions: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
Interventions: aflibercept 8 mg PFS; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 2
States / cities: Bellaire, Texas • The Woodlands, Texas

Conditions: Neovascular Age-related Macular Degeneration
Interventions: CLS-AX, Aflibercept; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Bakersfield, California • Fullerton, California + 28 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 50 Years to 100 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Ovarian Neoplasms
Interventions: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Neovascular Glaucoma
Interventions: Aflibercept; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 90 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Macular Degeneration
Interventions: VEGF Trap Eye; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 33
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 30 more

Conditions: Diabetic Macular Edema
Interventions: Aflibercept, Faricimab, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 85
States / cities: Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 78 more

Conditions: Age - Related Macular Degeneration (AMD)
Interventions: Intravitreal Aflibercept Injection (IAI); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 46 more

Conditions: Exudative Age-related Macular Degeneration
Interventions: Aflibercept; Drug
Lead sponsor: Palmetto Retina Center, LLC; Other
Eligibility: Not listed
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 6
States / cities: Augusta, Georgia • Lincoln, Nebraska • West Columbia, South Carolina + 3 more

Conditions: Neoplasms
Interventions: Ziv-Aflibercept, Ganetespib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)

Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD

Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Variable Interval Versus Set Interval Aflibercept for DME

Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab

Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept

Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept

Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD

Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration

Neovascular Age-related Macular Degeneration

AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites

Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma

Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)

Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910

Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas